Multicenter study of Klimonorm (R) by the Jenapharm firm for treating the climacteric syndrome
Czekanowski, R.; Stelmachow, J.; Radowicki, S.; Cekański, A.; Florczak, M.; Chlabicz, P.
Ginekologia Polska 66(4): 237-245
1995
ISSN/ISBN: 0017-0011 PMID: 8529942 Document Number: 447414
In our work we evaluated according to Kupperman Index the effectiveness of treating menopausal signs and symptoms during the therapy with estrogen--progestagen preparation Klimonorm firm Jenapharm. During 6 months observation increase in blood pressure was not observed, neither an increase in body weight in a group of 116 women was not observed. Among these, mean Kupperman index was decreased from 28.38 to 11.6 after 3 months and up to 5.47 after 6 months therapy with Klimonorm. These patients estimated this agent as very good and good in 93.21% tolerated as very good and good in 91.43% and 91.59% of these patients planned to continue treatment with Klimonorm.